Personalis

Sequence tumor and normal tissue samples from clinical trial participants.

Analyze genomic data to identify biomarkers associated with drug response.

Stratify patients based on biomarker status.

Evaluate drug efficacy in biomarker-positive and biomarker-negative patients.

Develop a companion diagnostic to identify responders in future clinical use.

Sequence tumor DNA and RNA to identify mutations.

Predict neoantigens based on tumor-specific mutations.

Synthesize peptides corresponding to the predicted neoantigens.

Administer neoantigen-based vaccine to stimulate an immune response against the tumor.

Monitor immune response and clinical outcomes.

Sequence tumor samples from patients who have developed resistance to a targeted therapy.

Compare genomic profiles of pre-treatment and post-treatment samples.

Identify genomic alterations associated with resistance.

Develop strategies to overcome resistance, such as combination therapies or alternative targets.

Test novel strategies in preclinical models.

Define genomic biomarkers associated with drug response.

Screen patients for the presence of these biomarkers.

Enroll biomarker-positive patients in the clinical trial.

Evaluate drug efficacy in the enriched population.

Demonstrate improved response rates and clinical outcomes.